CClinicalTrials.gg
CompletedNCT03326778INCAUpdated Aug 26, 2021

Registry to Gather Long-time Results After Surgical Aortic Valve Replacement With a "Rapid Deployment Aortic Valve Prothesis (Edwards Intuity) Combined With Bypss Surgery (CABG)

An observational study in Aortic Valve Stenosis and Coronary Artery Disease, sponsored by Campus Bad Neustadt. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-26.

Sponsored by Campus Bad Neustadt · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
220
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospctive, unrandomized multicentric registry which will enrol patients with an indication for aortc valve replacement combined with myocardial reperfusion (CABG). The registry will collect patient specific baseline data and established risk scores (Logistic Euroscore I \& II, STS-Score, KBA Score) to enable us to make an estimate about the perioperative risks.

Read the detailed description

Aortic replacement combined with coronary bypass surgery has an impact on the risk profile for the direct postoperative course and also on the long-time survival perspective.

The advantage of rapid deployment aortic valve prostheses, like the Edward Intuity Elite Valve that is used in this registry, is the greater ease of implantation, because only a few sutures are necessary to secure the device compared to a conventional prosthesis, where more then ten sutures are needed. In procedures where the aortic valve replacement (AVR) is combined with a coronary artery bypass graft (CABG), the use of a rapid deployment valve can shorten the duration of cardiac ischemia and the overall intervention duration, which possibly has an influence on clinical results.

02

Conditions studied

  • Aortic Valve Stenosis
  • Coronary Artery Disease

Keywords

  • Aortic Valve Stenosis
  • Rapid deployment Valve
  • CABG
  • Edwards Intuity Elite
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with an indication for AVR combined with CABG who will receive an Edwards Intuity Elite rapid deployment aortic valve prosthesis.

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria:
  • patients with aortic valve stenosis and coronary heart disease with indication for AVR and CABG
  • patients in who the Edwards Intuity Elite valve is to be implanted
  • patients who are planned to receive at least one coronary bypass
  • patients who have signed an informed consent form

Exclusion Criteria:

  • Exclusion Criteria:
  • emergency surgery
  • re-operation (i.e. any previous opening of pericardium)
  • additional heart diseases requiring heart surgery (e. g. subvalvular myectomy and ablation, but not atrial auricle closure or resection)
  • legal incapacity or other circumstances that impair the patient's ability to understand the nature, meaning or extent of the trial
  • patients wanting a mechanical prosthesis
  • patients with contraindications for the Edwards Intuity Elite Valve
  • acute endocarditis or other systemic infections
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
220 participants (actual)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • AVR + CABG

    Patient receiving AVR combined with CABG

    Procedure: AVR and CABG

Interventions

  • ProcedureAVR and CABG

    Combined AVR with CABG

05

What researchers measure

Primary outcomes

  1. all-cause mortality

    death from any reason

    Time frame: 30 Days

06

Study locations

1 site
  • Campus Bad Neustadt
    Bad Neustadt An Der Saale, Bavaria 97616, Germany
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03326778
Lead sponsor
Campus Bad Neustadt
Collaborators
Edwards Lifesciences, Software for Trials Europe GmbH, Institut für Pharmakologie und Präventive Medizin
Responsible party
Sponsor
First posted
Oct 31, 2017
Start date
Nov 26, 2017
Primary completion
Dec 6, 2019
Completion
Jul 1, 2020
Last update
Aug 26, 2021

Study contacts

Anno Diegeler, Prof.
principal investigator · Campus Bad Neustadt

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion